Menu
Menu
Orchid Pharma has received DCGI approval to market a new antibiotic combination, Cefepime and Enmetazobactam, as a dry powder injectable for treating complicated urinary tract infections and hospital-acquired pneumonia. With the DCGI's nod, Orchid Pharma is set to revolutionize the treatment of serious infections with its new Cefepime and Enmetazobactam antibiotic, targeting conditions like complicated UTIs and ventilator-associated pneumonia. The approval of Orchid Pharma's new antibiotic combination by the DCGI marks a significant advancement in the fight against complicated urinary tract infections, hospital-acquired pneumonia, and bacteremia. Orchid Pharma's new Cefepime and Enmetazobactam combination, approved by the DCGI, offers a potent solution for treating severe bacterial infections, including acute pyelonephritis and hospital-acquired pneumonia. Orchid Pharma celebrates a major milestone with the DCGI's approval of its Cefepime and Enmetazobactam antibiotic, designed to combat complicated urinary tract infections and serious respiratory conditions. The DCGI has approved Orchid Pharma's innovative antibiotic combination of Cefepime and Enmetazobactam, a dry powder injectable that promises to improve treatment outcomes for severe infections. Orchid Pharma's newly approved Cefepime and Enmetazobactam antibiotic by the DCGI represents a crucial development in addressing complicated UTIs and hospital-acquired pneumonia, including VAP. The DCGI approval of Orchid Pharma's Cefepime and Enmetazobactam marks an important step forward in the treatment of complex bacterial infections, offering new hope for patients with serious conditions.